WO2004017906A2 - Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) - Google Patents
Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) Download PDFInfo
- Publication number
- WO2004017906A2 WO2004017906A2 PCT/US2003/026251 US0326251W WO2004017906A2 WO 2004017906 A2 WO2004017906 A2 WO 2004017906A2 US 0326251 W US0326251 W US 0326251W WO 2004017906 A2 WO2004017906 A2 WO 2004017906A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activity
- mmp
- modulated
- mmp activity
- symptoms
- Prior art date
Links
- 0 C[C@@](CC1)([C@@]2(C(C3CC4)C([C@@]5O)C(C=O)=O)O[C@]2C[C@]3(*)[C@@]4(CC2*)OC2=O)C5=CC1=O Chemical compound C[C@@](CC1)([C@@]2(C(C3CC4)C([C@@]5O)C(C=O)=O)O[C@]2C[C@]3(*)[C@@]4(CC2*)OC2=O)C5=CC1=O 0.000 description 1
- SAPWXZIIGGUJDU-KYMAGWAASA-N C[C@]1(C(CC2)C(C([C@H](C([C@]3(C)CC4)=C[C@H]4O)N)C(C=O)=O)[C@@]33O[C@@H]3C1)[C@@]2(CC1)OC1=O Chemical compound C[C@]1(C(CC2)C(C([C@H](C([C@]3(C)CC4)=C[C@H]4O)N)C(C=O)=O)[C@@]33O[C@@H]3C1)[C@@]2(CC1)OC1=O SAPWXZIIGGUJDU-KYMAGWAASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004529805A JP2005536536A (en) | 2002-08-23 | 2003-08-22 | Modulation of matrix metalloproteinase (MMP) activity by aldosterone blockers |
BRPI0313693-0A BR0313693A (en) | 2002-08-23 | 2003-08-22 | modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker (s) |
MXPA05002062A MXPA05002062A (en) | 2002-08-23 | 2003-08-22 | Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s). |
AU2003259979A AU2003259979A1 (en) | 2002-08-23 | 2003-08-22 | Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
EP03793245A EP1542698A4 (en) | 2002-08-23 | 2003-08-22 | Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
CA002495376A CA2495376A1 (en) | 2002-08-23 | 2003-08-22 | Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40529202P | 2002-08-23 | 2002-08-23 | |
US60/405,292 | 2002-08-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004017906A2 true WO2004017906A2 (en) | 2004-03-04 |
WO2004017906A3 WO2004017906A3 (en) | 2004-07-01 |
Family
ID=31946847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/026251 WO2004017906A2 (en) | 2002-08-23 | 2003-08-22 | Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040048840A1 (en) |
EP (1) | EP1542698A4 (en) |
JP (1) | JP2005536536A (en) |
AU (1) | AU2003259979A1 (en) |
BR (1) | BR0313693A (en) |
CA (1) | CA2495376A1 (en) |
MX (1) | MXPA05002062A (en) |
WO (1) | WO2004017906A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123561A3 (en) * | 2011-03-17 | 2013-01-03 | Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum | Agent for prophylaxis and treatment of age-associated diseases and disorders and for prolonging life |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008007419A (en) * | 2006-06-27 | 2008-01-17 | Ifuji Sangyo Co Ltd | Hydrolyzed shell membrane produced from shell membrane of hen's egg with proteinase, method for producing the same and functional material added therewith |
EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
FR2917975B1 (en) * | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | COMPOSITIONS AND TREATMENT OF CARDIAC INSUFFICIENCY IN NON-HUMAN MAMMAL ANIMALS |
US20090270356A1 (en) * | 2008-04-28 | 2009-10-29 | Ceva Sante Animale Sa | Compositions and treatments of heart failure in non-human mammal animals |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668124A (en) * | 1992-04-21 | 1997-09-16 | Weber; Karl T. | Use of aldosterone antagonists to inhibit myocardial fibrosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74141C2 (en) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants) |
US20020132001A1 (en) * | 2000-05-11 | 2002-09-19 | Garthwaite Susan M. | Aldosterone antagonist composition for release during aldosterone acrophase |
AU1604001A (en) * | 2000-06-13 | 2001-12-24 | Pharmacia Corp | Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
EP1368009A2 (en) * | 2000-07-27 | 2003-12-10 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
-
2003
- 2003-08-22 AU AU2003259979A patent/AU2003259979A1/en not_active Abandoned
- 2003-08-22 US US10/645,564 patent/US20040048840A1/en not_active Abandoned
- 2003-08-22 WO PCT/US2003/026251 patent/WO2004017906A2/en not_active Application Discontinuation
- 2003-08-22 BR BRPI0313693-0A patent/BR0313693A/en not_active Application Discontinuation
- 2003-08-22 CA CA002495376A patent/CA2495376A1/en not_active Abandoned
- 2003-08-22 MX MXPA05002062A patent/MXPA05002062A/en unknown
- 2003-08-22 EP EP03793245A patent/EP1542698A4/en not_active Withdrawn
- 2003-08-22 JP JP2004529805A patent/JP2005536536A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668124A (en) * | 1992-04-21 | 1997-09-16 | Weber; Karl T. | Use of aldosterone antagonists to inhibit myocardial fibrosis |
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [Online] COATS, ANDREW J.S.: 'Exciting new drugs on the horizon: Eplerenone, a selective aldosterone receptor antagonist (SARA)', XP002975274 Retrieved from STN Database accession no. 2001:495110 & INTERNATIONAL JOURNAL OF CARDIOLOGY vol. 80, no. 1, August 2001, pages 1 - 4 * |
See also references of EP1542698A2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123561A3 (en) * | 2011-03-17 | 2013-01-03 | Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum | Agent for prophylaxis and treatment of age-associated diseases and disorders and for prolonging life |
Also Published As
Publication number | Publication date |
---|---|
JP2005536536A (en) | 2005-12-02 |
EP1542698A2 (en) | 2005-06-22 |
AU2003259979A1 (en) | 2004-03-11 |
MXPA05002062A (en) | 2005-06-08 |
AU2003259979A8 (en) | 2004-03-11 |
EP1542698A4 (en) | 2006-07-19 |
WO2004017906A3 (en) | 2004-07-01 |
US20040048840A1 (en) | 2004-03-11 |
CA2495376A1 (en) | 2004-03-04 |
BR0313693A (en) | 2007-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI222360B (en) | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives | |
JP4599062B2 (en) | Pyridylamide as an angiogenesis inhibitor | |
AU737312B2 (en) | Treatment and prevention of adhesions | |
RU2322984C2 (en) | Combinations for treating immuno-inflammatory disorders | |
SK138799A3 (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
JPH09505809A (en) | Inhibition of smooth muscle migration and proliferation by hydroxycarbazole compounds | |
JP6273072B2 (en) | Compositions and methods of treating cardiac fibrosis with ifetroban | |
US20200030298A1 (en) | Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor Antagonists | |
DE60036122T2 (en) | USE OF EPLERENONE FOR THE TREATMENT OF RESTENOSIS | |
WO2004017906A2 (en) | Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) | |
FI103868B (en) | A process for preparing a pharmaceutical composition for preventing fibrin precipitation or adherent growth | |
JP2002538226A (en) | Treatment of thrombosis by using a combination of factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), GPIIb / IIIa antagonist, low molecular weight heparin or heparin | |
ES2858551T3 (en) | Thromboxane receptor antagonists | |
US6924303B2 (en) | Analgesic and anti-inflammatory compositions containing COX-2 inhibitors | |
US20080161274A1 (en) | Compounds and methods for inhibition of bone loss | |
US5736561A (en) | Vascular hypertrophy suppressor | |
US20040220249A1 (en) | Prevention of surgical adhesions using selective COX-2 inhibitors | |
EP1333855A1 (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders | |
WO2015107139A1 (en) | Compounds for use as antifibrinolytic agents | |
JP2008508316A (en) | Treatment of benign prostatic hyperplasia | |
Smith | Management of chronic degenerative mitral valve disease in dogs | |
US20110034504A1 (en) | Agent for preventing and/or treating vascular diseases | |
WO2011035026A1 (en) | Methods for treating myocardial disorders | |
WO2001076587A1 (en) | Remedies for diseases due to stenotic lesions of blood vessel | |
JP2005526128A (en) | Prevention or treatment of abnormal lipoproteins, cholestasis and atherosclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003793245 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2495376 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/002062 Country of ref document: MX Ref document number: 2004529805 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003793245 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003793245 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0313693 Country of ref document: BR |